Search Results

You are looking at 21 - 30 of 2,569 items for :

  • Refine by Access: All x
Clear All
Full access

Arjun Gupta, Avash Das, Raseen Tariq, Nizar Bhulani, Naveen Premnath, Dipesh Solanky, Ryan D. Frank, David Johnson, Sahil Khanna, and Muhammad S. Beg

questionable. Within the past few decades, ICU outcomes have improved drastically, owing to better management techniques, early identification of sicker patients, and more lenient admission criteria for ICUs. One recent study reported a 35% relative decrease

Full access

Rowan T. Chlebowski, Aaron K. Aragaki, and Garnet L. Anderson

,739 postmenopausal women with prior hysterectomy 12 ( Figure 1 ). The primary outcome monitored for benefit was coronary heart disease and the primary outcome monitored for harm was invasive breast cancer. A global index of time to first Figure 1 Women

Full access

Nora Janjan

Patient outcomes have become an integral end point as the nation’s medical training, research, and delivery system transforms into a patient-centered, value-based accreditation and reimbursement system. The components of patient-centered outcomes

Full access

Arjun Gupta, Raseen Tariq, Ryan D. Frank, Gary W. Jean, Muhammad S. Beg, Darrell S. Pardi, David H. Johnson, and Sahil Khanna

Thus, elucidating the epidemiology of CDI and its impact on outcomes in patients with cancer is imperative. We used the National Hospital Discharge Survey (NHDS) database to evaluate the incidence of CDI in patients with both solid organ and

Full access

Paul A. Glare

palliative care-type treatment, given that this term is perceived to cause less distress to patients, their caregivers, and clinicians. 7 , 21 Symptom control and, therefore, quality of life are the end points of supportive care, while the main outcome is

Full access

Ashley E. Rosko, Sarah Wall, Robert Baiocchi, Don M. Benson, Jonathan E. Brammer, John C. Byrd, Yvonne A. Efebera, Kami Maddocks, Kerry A. Rogers, Desiree Jones, Lara Sucheston-Campbell, Hancong Tang, Hatice Gulcin Ozer, Ying Huang, Christin E. Burd, and Michelle J. Naughton

(mPhenoAge), has recently been reported, which is able to capture risk of adverse clinical outcomes across diverse tissue types 19 ; mPhenoAge has not yet been evaluated in a population with blood cancer. In this study, we explored mPhenoAge, markers of

Full access

Mostafa R. Mohamed, Erika Ramsdale, Kah Poh Loh, Huiwen Xu, Amita Patil, Nikesha Gilmore, Spencer Obrecht, Megan Wells, Ginah Nightingale, Katherine M. Juba, Bryan Faller, Adedayo Onitilo, Thomas Bradley, Eva Culakova, Holly Holmes, and Supriya G. Mohile

supportive care medications can increase the potential for clinically significant drug–drug interactions and adverse outcomes. 8 Polypharmacy is also associated with an increased risk of taking potentially inappropriate medications (PIMs; medications with a

Full access

Emily van Seventer, J. Peter Marquardt, Amelie S. Troschel, Till D. Best, Nora Horick, Chinenye Azoba, Richard Newcomb, Eric J. Roeland, Michael Rosenthal, Christopher P. Bridge, Joseph A. Greer, Areej El-Jawahri, Jennifer Temel, Florian J. Fintelmann, and Ryan D. Nipp

Background Patients with cancer often experience loss of skeletal muscle, which adversely impacts clinical outcomes. 1 , 2 Although most patients with cancer experience some degree of muscle loss, severe muscle loss contributes to approximately 20

Full access

Sarguni Singh, Megan Eguchi, Sung-Joon Min, and Stacy Fischer

palliative care consultation remains limited for patients in SNFs. 10 We sought to understand clinical outcomes of patients with stage II–IV pancreatic, colorectal, lung, and bladder cancers who discharge to an SNF compared with patients who discharge to home

Full access

Mohammad Abu Zaid, Paul C. Dinh Jr, Patrick O. Monahan, Chunkit Fung, Omar El-Charif, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Ryan Cook, Sandra Althouse, Shirin Ardeshir-Rouhani-Fard, Howard D. Sesso, Robert Huddart, Taisei Mushiroda, Michiaki Kubo, M. Eileen Dolan, Lawrence H. Einhorn, Sophie D. Fossa, Lois B. Travis, and for the Platinum Study Group

-wide association studies associated with increased risk for hypogonadism. 11 No study, however, has examined the prevalence of hypogonadism in North American TCS and its relationship to adverse health outcomes (AHOs). Most TCS have had one testicle (or both